RTTNews | Dec 16, 2021 10:49AM EST

10:49 Thursday, December 16, 2021 (RTTNews.com) - Shares of uniQure N.V. (QURE) are slipping over 23% on Thursday morning after the gene therapy company provided clinical update on first patients in phase I/II clinical trial of AMT-130 gene therapy for the treatment of Huntington's Disease.

QURE is currently trading at $21.94, down $6.81 or 23.67%, on the Nasdaq.

Two of the four enrolled patients received AMT-130, and two patients experienced an imitation (sham) surgery in this randomized, blinded clinical trial being conducted in the United States.

"We are pleased with these data that support the tolerability of AMT-130, a potential one-time gene-therapy approach for Huntington's disease," stated Ricardo Dolmetsch, president of research and development at uniQure.

The company said Neurofilament Light Chain (NfL) rose as expected immediately following surgery and returned to baseline in treated patients.

The company will reveal efficacy data including volumetric MRI changes after patients in the first two cohorts are unblinded.

Read the original article on RTTNews ( https://www.rttnews.com/3249987/what-is-hurting-uniqure-stock.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved